Skip to main content

Table 6 Sensitivity analysis: response/tolerance analysis at 1 year excluding patients having stopped TNFi due to other reasons than ineffectiveness and adverse events and imputing patients having discontinued the TNFi because of remission as being responders

From: Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort

Outcome N OR 95% CI p
ASAS20 89 0.20 0.06; 0.62 0.008
ASAS40 89 0.25 0.07; 0.78 0.02
BASDAI50 89 0.24 0.07; 0.72 0.01
ASDAS improvement ≥ 1.1 78 0.32 0.10; 0.93 0.04
ASDAS < 2.1 82 0.26 0.06; 0.91 0.04
ASDAS improvement ≥ 2 78 0.08 0.01; 0.43 0.006
ASDAS < 1.3 82 0.14 0.02; 0.62 0.02
  1. Analyses are adjusted for diagnostic delay, MASES, BASDAI, and BMI. ASAS20 and ASAS40 20% and 40% improvement according to the ASAS criteria, respectively; ASDAS Ankylosing Spondylitis Disease Activity Score; BASDAI50 50% improvement in the BASDAI; nr-axSpA nonradiographic axial spondyloarthritis; TNF tumor necrosis factor